ACAD
33.35
+1.39
+4.35%
AEMD
0.24
+0.03
+11.89%
APRI
1.92
+0.01
+0.52%
ARNA
4.48
+0.15
+3.46%
ATEC
1.41
+0.01
+0.71%
CNAT
7.53
-0.22
-2.84%
CRXM
0.195
0.00
0.00%
CYTX
1.2
+0.01
+0.84%
DXCM
61.98
+1.82
+3.03%
GNMK
13.3
+0.01
+0.08%
HALO
14
+0.07
+0.50%
ILMN
187.62
+0.45
+0.24%
INNV
0.179
+0.049
+37.5096%
INO
8.33
+0.05
+0.54%
ISCO
0.059
-0.003
-4.0984%
ISIS
64.81
+1.44
+2.27%
LGND
76.23
+3.28
+4.50%
LPTN
2.47
-0.01
-0.40%
MBVX
1.86
+0.24
+14.81%
MEIP
1.75
+0.01
+0.57%
MNOV
3.59
+0.04
+1.13%
MRTX
29.11
+0.69
+2.43%
MSTX
0.498
-0.002
-0.3006%
NBIX
41.53
+2.75
+7.09%
NUVA
46.4
+1.8
+4.04%
ONCS
0.35
0.00
0.00%
ONVO
3.37
-0.29
-7.92%
OREX
7.75
+0.21
+2.79%
OTIC
35.63
+1.4
+4.09%
QDEL
27.5
+0.35
+1.29%
RCPT
160.05
+12.62
+8.56%
RGLS
17.26
+0.44
+2.62%
RMD
71.65
+0.1
+0.14%
SCIE
0.026
-0.006
-17.7419%
SPHS
0.55
-0.04
-6.76%
SRNE
11.36
-0.93
-7.57%
TROV
7
0.00
0.00%
VICL
0.9
-0.02
-2.46%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
+0.03
+2.24%
ACAD
33.35
+1.39
+4.35%
AEMD
0.24
+0.03
+11.89%
APRI
1.92
+0.01
+0.52%
ARNA
4.48
+0.15
+3.46%
ATEC
1.41
+0.01
+0.71%
CNAT
7.53
-0.22
-2.84%
CRXM
0.195
0.00
0.00%
CYTX
1.2
+0.01
+0.84%
DXCM
61.98
+1.82
+3.03%
GNMK
13.3
+0.01
+0.08%
HALO
14
+0.07
+0.50%
ILMN
187.62
+0.45
+0.24%
INNV
0.179
+0.049
+37.5096%
INO
8.33
+0.05
+0.54%
ISCO
0.059
-0.003
-4.0984%
ISIS
64.81
+1.44
+2.27%
LGND
76.23
+3.28
+4.50%
LPTN
2.47
-0.01
-0.40%
MBVX
1.86
+0.24
+14.81%
MEIP
1.75
+0.01
+0.57%
MNOV
3.59
+0.04
+1.13%
MRTX
29.11
+0.69
+2.43%
MSTX
0.498
-0.002
-0.3006%
NBIX
41.53
+2.75
+7.09%
NUVA
46.4
+1.8
+4.04%
ONCS
0.35
0.00
0.00%
ONVO
3.37
-0.29
-7.92%
OREX
7.75
+0.21
+2.79%
OTIC
35.63
+1.4
+4.09%
QDEL
27.5
+0.35
+1.29%
RCPT
160.05
+12.62
+8.56%
RGLS
17.26
+0.44
+2.62%
RMD
71.65
+0.1
+0.14%
SCIE
0.026
-0.006
-17.7419%
SPHS
0.55
-0.04
-6.76%
SRNE
11.36
-0.93
-7.57%
TROV
7
0.00
0.00%
VICL
0.9
-0.02
-2.46%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
+0.03
+2.24%
Home » PR Newswire, Syndication

Galmed Pharmaceuticals to Present at the Biotech Showcase™

Submitted by on January 6, 2015 – 6:00 am

TEL AVIV, Israel, Jan. 6, 2015 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that Josh Blacher, Chief Financial Officer, will present a company overview at the Seventh Annual Biotech Showcase™ conference in San Francisco, California on Wednesday, January 14, 2015 at 10:00 AM Pacific Standard Time. The presentation will be available live via webcast at http://galmedpharma.investorroom.com/.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading “Risk Factors” included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed’s current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.

SOURCE Galmed Pharmaceuticals Ltd.